Brought to you by 
Peptide Therapeutics to trade on London Stock Exchange
13 Jul 1999
Executive Summary
Peptide Therapeutics (developing allergy, asthma, and rheumatology vaccines and therapeutics) netted $37.4 million (UK24mm) through an IPO on the London Stock Exchange of 12.5mm shares at $3 (200p) per share, plus 600,000 shares on subscription.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Peptide Therapeutics to trade on London Stock Exchange
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice